Form 4: Ionis Pharma CBO Baroldi Reports Equity Transactions

Ionis Pharmaceuticals' Chief Business Officer, Joseph Baroldi, reported the vesting of restricted stock units and subsequent tax-related sales, alongside new equity grants.

Summary

• Joseph Baroldi, EVP, Chief Business Officer of Ionis Pharmaceuticals Inc. (IONS), reported several equity transactions.
• On January 15, 2026, Baroldi acquired 17,037 shares of common stock directly and 2,850 shares indirectly through his spouse, both resulting from the vesting of Restricted Stock Unit (RSU) awards.
• On January 16, 2026, Baroldi sold 6,907 shares directly at a weighted average price of $75.75 and his spouse sold 1,149 shares indirectly at $75.78. These sales were made to cover required tax withholding obligations.
• Baroldi was granted 25,800 Performance Restricted Stock Units (PRSUs) on January 15, 2026, which may vest based on the company's relative total shareholder return over a three-year period ending January 15, 2029. The reported number represents the maximum possible vesting (200% of target).
• Additionally, Baroldi received a grant of 9,675 RSUs directly and his spouse received 3,900 RSUs indirectly, both on January 15, 2026, with these RSUs vesting in four equal annual installments starting January 15, 2027.
• Following these transactions, Baroldi directly beneficially owns 40,431 shares of common stock and indirectly owns 4,772 shares through his spouse. He also holds derivative securities including 77,090 PRSUs (maximum) and 59,149 RSUs directly, and 9,374 RSUs indirectly through his spouse.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive. It details routine executive compensation events, including new equity grants which align executive interests with shareholders, and standard tax-related sales. No significant negative or positive operational news is present.

Positives

• The executive received new grants of Performance Restricted Stock Units (PRSUs) and Restricted Stock Units (RSUs), aligning executive incentives with shareholder value.
• Vesting of previous RSU awards indicates successful achievement of prior compensation milestones.

Negatives

• Sales of common stock occurred to cover tax withholding obligations, which is a routine event but reduces direct share ownership.

Risks

• The vesting of Performance Restricted Stock Units (PRSUs) is contingent on Ionis Pharmaceuticals' relative total shareholder return compared to a peer group over a three-year period, meaning the actual number of shares received could range from zero to the maximum reported amount of 25,800.

Future Outlook

The reporting person has future equity vesting events scheduled, including Performance Restricted Stock Units (PRSUs) that may vest by January 15, 2029, contingent on the company's relative total shareholder return, and Restricted Stock Units (RSUs) that will vest in four equal annual installments starting January 15, 2027.

Industry Context

This filing reflects routine executive compensation practices within the biotechnology and pharmaceutical industry, where equity awards like RSUs and PRSUs are common tools to align management incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• Equity-based compensation, including RSUs and PRSUs, is a standard practice for executive remuneration in the pharmaceutical and biotechnology sectors, comparable to companies like Biogen or Gilead Sciences.
• The use of performance-based vesting for PRSUs, tied to relative total shareholder return against a peer group, aligns with best practices in corporate governance to ensure executive pay is linked to market-relative performance.
• "Sell to cover" transactions for tax withholding are a common and expected occurrence when equity awards vest, reflecting standard tax compliance for executives across industries.

Corporate Governance

Related Party Transactions

• Transactions involving the reporting person's spouse are disclosed as indirect beneficial ownership, which is a standard related party disclosure for insider filings.

Stakeholder Impact

• Shareholders: The grant of new equity awards, particularly performance-based units, aligns executive incentives with shareholder value creation. Tax-related sales are routine and not indicative of a lack of confidence.
• Employees: Reflects the company's compensation strategy for executives, potentially setting a precedent for other equity award recipients.
• Management: Joseph Baroldi's compensation package is detailed, showing a mix of vested shares, tax-related sales, and new performance-based and time-based equity grants.

Next Steps

• Monitoring the vesting of Performance Restricted Stock Units (PRSUs) by January 15, 2029, based on relative total shareholder return.
• Observing the annual vesting of Restricted Stock Units (RSUs) starting January 15, 2027.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Joseph Baroldi, Form 4, SEC filing, insider trading, equity compensation, restricted stock units, performance restricted stock units, executive compensation, beneficial ownership